• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

白内障手术后眼部炎症和疼痛的管理：聚焦于溴芬酸钠滴眼液

Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution.

作者信息

Cho Hyung, Wolf Kenneth J, Wolf Eric J

机构信息

Department of Ophthalmology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.

出版信息

Clin Ophthalmol. 2009;3:199-210. doi: 10.2147/opth.s4806. Epub 2009 Jun 2.

DOI:10.2147/opth.s4806
PMID:19668566
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2709021/
Abstract

Recently, several new ophthalmic NSAID products have been introduced for commercial use in the United States. The purpose of this review is to briefly overview the ophthalmic NSAIDs currently in use and to discuss the management of postoperative ocular inflammation and pain following cataract surgery with a particular focus on bromfenac ophthalmic solution 0.09%. Bromfenac ophthalmic solution 0.09% is indicated for the reduction of ocular pain and inflammation following cataract surgery. Studies have shown that bromfenac ophthalmic solution 0.09% has equivalent efficacy to the other topical NSAIDs in reducing postsurgical inflammation and controlling pain. The unique chemical structure of bromfenac makes it both a potent inhibitor of the COX-2 enzyme and a highly lipophilic molecule that rapidly penetrates to produce early and sustained drug levels in all ocular tissues. Clinically, these pharmacokinetic features are manifested in a rapid reduction of postsurgical inflammation and pain with bid dosing. Bromfenac ophthalmic solution 0.09% is a versatile agent and is effective when used as either monotherapy or as an adjunct therapy to steroids.

摘要

最近，几种新型眼科非甾体抗炎药产品已在美国投入商业使用。本综述的目的是简要概述目前正在使用的眼科非甾体抗炎药，并讨论白内障手术后眼部炎症和疼痛的管理，特别关注0.09%溴芬酸钠眼药水。0.09%溴芬酸钠眼药水适用于减轻白内障手术后的眼部疼痛和炎症。研究表明，0.09%溴芬酸钠眼药水在减轻术后炎症和控制疼痛方面与其他局部用非甾体抗炎药具有同等疗效。溴芬酸独特的化学结构使其既是COX-2酶的强效抑制剂，又是高度亲脂性分子，能迅速渗透，在所有眼组织中产生早期和持续的药物水平。临床上，这些药代动力学特征表现为每日两次给药可迅速减轻术后炎症和疼痛。0.09%溴芬酸钠眼药水是一种多功能药物，作为单一疗法或作为类固醇的辅助疗法使用时均有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b49/2709021/ff5466ed0a0f/opth-3-199f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b49/2709021/63b69290b8de/opth-3-199f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b49/2709021/98a89f595112/opth-3-199f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b49/2709021/ff5466ed0a0f/opth-3-199f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b49/2709021/63b69290b8de/opth-3-199f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b49/2709021/98a89f595112/opth-3-199f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b49/2709021/ff5466ed0a0f/opth-3-199f3.jpg

相似文献

1
Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution.白内障手术后眼部炎症和疼痛的管理：聚焦于溴芬酸钠滴眼液
Clin Ophthalmol. 2009;3:199-210. doi: 10.2147/opth.s4806. Epub 2009 Jun 2.
2
Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence.用于治疗术后眼部疼痛和炎症的溴芬酸钠眼药水：安全性、有效性及患者依从性
Patient Prefer Adherence. 2014 Jun 25;8:925-31. doi: 10.2147/PPA.S46667. eCollection 2014.
3
Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials.溴芬酸钠滴眼液 0.07% 每日一次用于白内障手术：两项随机对照试验的结果。
Ophthalmology. 2014 Jan;121(1):25-33. doi: 10.1016/j.ophtha.2013.07.006. Epub 2013 Sep 8.
4
Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies.局部用溴芬酸钠治疗白内障手术后眼部疼痛和炎症的应用：已发表研究综述
Clin Ophthalmol. 2019 Aug 1;13:1439-1460. doi: 10.2147/OPTH.S208700. eCollection 2019.
5
Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain.每日一次给予溴芬酸钠滴眼液 0.09%治疗术后眼部炎症和疼痛。
Curr Med Res Opin. 2011 Sep;27(9):1693-703. doi: 10.1185/03007995.2011.597663. Epub 2011 Jul 14.
6
Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain.溴芬酸钠滴眼液（溴莫尼定）每日滴眼一次用于术后眼部炎症和疼痛的安全性和有效性。
Ophthalmology. 2011 Nov;118(11):2120-7. doi: 10.1016/j.ophtha.2011.04.035. Epub 2011 Jul 16.
7
Bromfenac Ophthalmic Solution 0.07%: A Review of Its Use After Cataract Surgery.0.07%溴芬酸眼用溶液：白内障手术后应用综述
Clin Drug Investig. 2015 Aug;35(8):525-9. doi: 10.1007/s40261-015-0309-3.
8
Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction.每日两次使用倍半水合溴芬酸钠治疗白内障摘除术后眼部炎症的最新进展。
Clin Ophthalmol. 2012;6:637-44. doi: 10.2147/OPTH.S23381. Epub 2012 Apr 27.
9
Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.0.09%溴芬酸钠眼药水（希佰润）用于术后眼部疼痛和炎症。
Ophthalmology. 2007 Sep;114(9):1653-62. doi: 10.1016/j.ophtha.2006.12.029. Epub 2007 Apr 19.
10
Efficacy and safety of bromfenac 0.075% formulated in DuraSite for pain and inflammation in cataract surgery.在白内障手术中，DuraSite 配方的 0.075%溴芬酸的疗效和安全性与疼痛和炎症。
Expert Opin Pharmacother. 2019 Oct;20(14):1703-1709. doi: 10.1080/14656566.2019.1645834. Epub 2019 Jul 25.

引用本文的文献

1
Effect of Strabismus Surgery on Meibomian Glands, Ocular Surface Parameters, and Conjunctival Impression Cytology.斜视手术对睑板腺、眼表参数及结膜印迹细胞学的影响。
Diagnostics (Basel). 2025 May 21;15(10):1291. doi: 10.3390/diagnostics15101291.
2
Clobetasol propionate for post-cataract surgery pain and inflammation.丙酸氯倍他索用于白内障术后疼痛和炎症。
Ann Med Surg (Lond). 2024 Oct 7;86(11):6395-6398. doi: 10.1097/MS9.0000000000002619. eCollection 2024 Nov.
3
Effect of Bromfenac on Reducing Neuroinflammation in an Ischemia-Reperfusion Glaucoma Model.

本文引用的文献

1
Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels.0.4%酮咯酸与0.09%溴芬酸谷值给药时的比较：药物的水相吸收及前列腺素E2水平
J Cataract Refract Surg. 2008 Sep;34(9):1509-12. doi: 10.1016/j.jcrs.2008.05.023.
2
Topical ocular delivery of NSAIDs.非甾体抗炎药的眼部局部给药。
AAPS J. 2008 Jun;10(2):229-41. doi: 10.1208/s12248-008-9024-9. Epub 2008 Apr 25.
3
The systemic safety of bromfenac ophthalmic solution 0.09%.0.09%溴芬酸钠眼药水的全身安全性。
溴芬酸对缺血再灌注性青光眼模型中神经炎症的影响。
Cells. 2024 Jun 17;13(12):1046. doi: 10.3390/cells13121046.
4
Chitosan and Anionic Solubility Enhancer Sulfobutylether-β-Cyclodextrin-Based Nanoparticles as Dexamethasone Ophthalmic Delivery System for Anti-Inflammatory Therapy.壳聚糖与基于阴离子溶解性增强剂磺丁基醚-β-环糊精的纳米颗粒作为地塞米松眼用给药系统用于抗炎治疗
Pharmaceutics. 2024 Feb 16;16(2):277. doi: 10.3390/pharmaceutics16020277.
5
0.2% Betamethasone Sodium Phosphate: A Multicenter, Randomized, Double-Masked Study to Compare Its Ocular Safety, Tolerability, and Efficacy to Vehicle in Cataract Surgery Subjects.0.2%倍他米松磷酸钠：一项多中心、随机、双盲研究，比较其在白内障手术患者中与赋形剂相比的眼部安全性、耐受性和疗效。
Clin Ophthalmol. 2023 Aug 5;17:2219-2230. doi: 10.2147/OPTH.S419857. eCollection 2023.
6
Dry eye parameters measured with an ocular surface analyzer in eyes after vitrectomy for vitreomacular interface disorders.玻璃体黄斑界面疾病行玻璃体切割术后眼的眼表面分析仪测量的干眼参数。
Indian J Ophthalmol. 2023 Apr;71(4):1551-1555. doi: 10.4103/IJO.IJO_3029_22.
7
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets.非感染性角膜损伤的治疗：诊断试剂、治疗药物及未来靶点的综述。
Drugs. 2022 Feb;82(2):145-167. doi: 10.1007/s40265-021-01660-5. Epub 2022 Jan 13.
8
Comparison of VEGF level in tears post phacoemulsification between non-proliferative diabetic retinopathy and non-diabetic patients.非增殖性糖尿病视网膜病变患者与非糖尿病患者白内障超声乳化术后泪液中血管内皮生长因子水平的比较。
J Diabetes Metab Disord. 2021 Aug 20;20(2):2073-2079. doi: 10.1007/s40200-021-00875-3. eCollection 2021 Dec.
9
Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.眼科中的皮质类固醇：药物输送创新、药理学、临床应用和未来展望。
Drug Deliv Transl Res. 2021 Jun;11(3):866-893. doi: 10.1007/s13346-020-00843-z.
10
Persistently Worsened Tear Break-up Time and Keratitis in Unilateral Pseudophakic Eyes after a Long Postoperative Period.术后长期单侧人工晶状体眼的泪膜破裂时间持续恶化及角膜炎
Biomedicines. 2020 Apr 5;8(4):77. doi: 10.3390/biomedicines8040077.
J Ocul Pharmacol Ther. 2007 Dec;23(6):601-12. doi: 10.1089/jop.2007.0040.
4
Nepafenac-associated corneal melt.奈帕芬胺相关性角膜溶解
J Cataract Refract Surg. 2007 Nov;33(11):1974-5. doi: 10.1016/j.jcrs.2007.06.043.
5
Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use.局部使用溴芬酸钠后史蒂文斯-约翰逊综合征中的角膜溶解和穿孔
J Cataract Refract Surg. 2007 Sep;33(9):1644-6. doi: 10.1016/j.jcrs.2007.04.041.
6
Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac.接受奈帕芬酸治疗的患者在白内障超声乳化术后发生具有视觉意义的人工晶状体性黄斑水肿的发生率。
J Cataract Refract Surg. 2007 Sep;33(9):1546-9. doi: 10.1016/j.jcrs.2007.05.018.
7
In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.萘普生、安芬那酸、酮咯酸和溴芬酸的体内药代动力学及体外药效学
J Cataract Refract Surg. 2007 Sep;33(9):1539-45. doi: 10.1016/j.jcrs.2007.05.015.
8
The role of NSAIDs in the management of postoperative ophthalmic inflammation.非甾体抗炎药在术后眼部炎症管理中的作用。
Drugs. 2007;67(9):1291-308. doi: 10.2165/00003495-200767090-00004.
9
Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.0.09%溴芬酸钠眼药水（希佰润）用于术后眼部疼痛和炎症。
Ophthalmology. 2007 Sep;114(9):1653-62. doi: 10.1016/j.ophtha.2006.12.029. Epub 2007 Apr 19.
10
Cystoid macular edema after phacoemulsification: risk factors and effect on visual acuity.白内障超声乳化术后的黄斑囊样水肿：危险因素及对视力的影响。
Can J Ophthalmol. 2006 Dec;41(6):699-703. doi: 10.3129/i06-062.